10.56

2.22% -0.2524

Wave Life Sciences Ltd (WVE)

Overview News Price History Option Chain Financials Why WVE Down? Discussions Forecast

Wave Life Sciences Ltd stock is traded at $10.56, with a volume of 197.56K. It is down -2.22% in the last 24 hours and down -2.13% over the past month. WAVE Life Sciences Ltd is a clinical-stage biotechnology company focused on unlocking the broad potential of RNA medicines also known as oligonucleotides, targeting ribonucleic acid (RNA), to transform human health. RNA medicines platform, PRISM, combines multiple modalities, chemistry innovation, and deep insights into human genetics to deliver scientific breakthroughs that treat both rare and prevalent disorders. Its toolkit of RNA-targeting modalities includes RNA editing, antisense silencing, and RNA interference, providing capabilities for designing and sustainably delivering candidates that optimally address disease biology. Its programs are for rare and prevalent diseases, including alpha-1 antitrypsin deficiency, obesity, Duchenne muscular dystrophy, and Huntington's disease.

Previous Close:

$10.81

Open:

$10.8

24h Volume:

197.56K

Relative Volume:

0.21

Market Cap:

$1.61B

Revenue:

$53.61M

Net Income/Loss:

$-142.52M

P/E Ratio:

-9.5114

EPS:

-1.11

Net Cash Flow:

$-141.83M

1W Performance:

+3.83%

1M Performance:

-2.13%

6M Performance:

+80.38%

1Y Performance:

+54.65%

1-Day Range:

$10.47

$10.89

1-Week Range:

$8.57

$10.96

52-Week Range:

$4.25

$16.73

Wave Life Sciences Ltd Stock (WVE) Company Profile

Name

Wave Life Sciences Ltd

Sector

Healthcare (1172)

Industry

Biotechnology (680)

Phone

617-949-2900

Address

7 STRAITS VIEW, SINGAPORE

Employee

288

Twitter

@WAVELifeSci

Next Earnings Date

2025-03-04

Latest SEC Filings

WVE's Discussions on Twitter

Compare WVE with other stocks

Stocks	Price	Market Cap	Revenue	Net Income	Cash Flow	EPS
WVE Wave Life Sciences Ltd	10.55	1.61B	53.61M	-142.52M	-141.83M	-1.11
VRTX Vertex Pharmaceuticals Inc	500.80	130.96B	11.02B	-535.60M	-978.00M	-2.20
REGN Regeneron Pharmaceuticals Inc	679.64	75.53B	14.20B	4.41B	3.54B	38.28
ARGX Argen X Se Adr	577.94	35.07B	2.19B	833.04M	-1.28B	12.71
ALNY Alnylam Pharmaceuticals Inc	241.15	31.72B	2.25B	-278.16M	-42.59M	-2.17
ONC Beigene Ltd Adr	249.12	26.76B	3.32B	-860.46M	-1.04B	-8.32

Wave Life Sciences Ltd Stock (WVE) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Feb-25-25	Initiated	Jefferies	Buy
Oct-16-24	Upgrade	Raymond James	Outperform → Strong Buy
Sep-27-24	Resumed	JP Morgan	Overweight
Sep-19-24	Initiated	B. Riley Securities	Buy
Sep-09-24	Initiated	JP Morgan	Overweight
May-15-24	Initiated	Wells Fargo	Overweight
Dec-19-23	Upgrade	Leerink Partners	Market Perform → Outperform
Jul-05-23	Initiated	Raymond James	Outperform
May-24-23	Downgrade	Jefferies	Buy → Hold
Dec-15-20	Resumed	H.C. Wainwright	Buy
Oct-23-20	Initiated	RBC Capital Mkts	Sector Perform
Dec-31-19	Downgrade	SVB Leerink	Outperform → Mkt Perform
Nov-01-19	Initiated	Guggenheim	Buy
Jul-15-19	Initiated	Cowen	Market Perform
Apr-17-19	Reiterated	H.C. Wainwright	Buy
Aug-07-18	Initiated	Stifel	Buy
Jul-23-18	Initiated	H.C. Wainwright	Buy
Mar-19-18	Reiterated	Mizuho	Buy
Feb-15-17	Initiated	H.C. Wainwright	Buy
Nov-10-16	Resumed	Leerink Partners	Outperform
Dec-07-15	Initiated	JMP Securities	Mkt Outperform
Dec-07-15	Initiated	Jefferies	Buy
Dec-07-15	Initiated	Leerink Partners	Outperform
Dec-07-15	Initiated	Sun Trust Rbsn Humphrey	Buy

View All

Wave Life Sciences Ltd Stock (WVE) Latest News

Mar 12, 2025

Wave Life Sciences’ SWOT analysis: RNA editing pioneer’s stock faces pivotal year - Investing.com

Mar 12, 2025

Mar 10, 2025

Mizuho maintains WAVE Life Sciences Outperform rating - Investing.com India

Mar 10, 2025

Reviewing Wave Life Sciences (NASDAQ:WVE) & Rhythm Pharmaceuticals (NASDAQ:RYTM) - Defense World

Mar 10, 2025

Mar 09, 2025

Paul Bolno Sells 169,025 Shares of Wave Life Sciences Ltd. (NASDAQ:WVE) Stock - Defense World

Mar 09, 2025

Mar 08, 2025

HC Wainwright Cuts Earnings Estimates for Wave Life Sciences - Defense World

Mar 08, 2025

Wave Life Sciences (NASDAQ:WVE) Rating Increased to Hold at StockNews.com - Defense World

Mar 08, 2025

Q1 EPS Forecast for Wave Life Sciences Decreased by Analyst - Defense World

Mar 08, 2025

Mar 07, 2025

Wave Life Sciences CEO Paul Bolno sells shares worth $1.62 million - Investing.com

Mar 07, 2025

Commit To Purchase Wave Life Sciences At $7.50, Earn 25.6% Annualized Using Options - Nasdaq

Mar 07, 2025

Wave Life Sciences (NASDAQ:WVE) Earns “Buy” Rating from HC Wainwright - Defense World

Mar 07, 2025

Analysts Set Expectations for WVE Q1 Earnings - Defense World

Mar 07, 2025

Mar 06, 2025

H.C. Wainwright maintains $22 target on WAVE Life Sciences stock - Investing.com India

Mar 06, 2025

Mar 05, 2025

Wave Life Sciences’ Earnings Call Highlights Progress and Challenges - TipRanks

Mar 05, 2025

Wave Life Sciences Ltd. (NASDAQ:WVE) Q4 2024 Earnings Call Transcript - MSN

Mar 05, 2025

Truist maintains Buy rating on WAVE Life Sciences stock, $36 target By Investing.com - Investing.com South Africa

Mar 05, 2025

RBC Trims Price Target on Wave Life Sciences to $14 From $15, Keeps Sector Perform, Speculative Risk - Marketscreener.com

Mar 05, 2025

Rhumbline Advisers Buys 17,316 Shares of Wave Life Sciences Ltd. (NASDAQ:WVE) - Defense World

Mar 05, 2025